

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Honliv Healthcare Management Group Company Limited

宏力醫療管理集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9906)

QUARTERLY UPDATE ON STATUS OF RESUMPTION

This announcement is made by Honliv Healthcare Management Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.24A of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 19 March 2026, 25 March 2026 and 21 April 2026 (the “**Announcements**”) in relation to, among other things, (i) the resignation of PricewaterhouseCoopers (“**PwC**”) as auditor; (ii) the appointment of HLB Hodgson Impey Cheng Limited (“**HLB**”) as the new auditor; and (iii) the delay in publication of 2025 annual results. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

RECENT DEVELOPMENT OF THE GROUP

Financial information

It is estimated that the audit of the 2025 Annual Results will be completed by the end of July 2026. The Company will publish the 2025 Annual Results and despatch the 2025 Annual Report as soon as practicable.

Independent investigation

The Independent Committee established by the Audit Committee has appointed Zhonghui Certified Public Accountants LLP (中匯會計師事務所(特殊普通合夥)) to assist them in conducting an independent forensic investigation on the issues raised by the Auditor (the “**Independent Investigation**”).

The Company has also appointed an independent internal control consultant Zhonghui Management Consultation Co., Ltd. (中匯管理諮詢有限公司) to conduct an independent internal control review on the Group’s internal control system (the “**Internal Control Review**”).

The Company will make further announcement(s) as and when appropriate to update the Shareholders and potential investors of the Company on the latest progress and outcome of the Independent Investigation and the Internal Control Review.

Business operation

The Company is a healthcare services provider in the PRC. The business operations and development of the Group remain as usual in all material aspects and in the same manner as it has operated. The Board will continue to assess and monitor the impact (if any) of the suspension of trading in the shares of the Company (the “**Share(s)**”) on the operations and financial performance of the Group and make appropriate measures, including publication of announcement(s) in relation to the business operations of the Group, as and when appropriate.

The 2025 Annual Results is expected to be published by the end of July 2026 following the completion of the audit of the 2025 Annual Results and the approval of the Board for its publication. Shareholders are advised to access and review the 2025 Annual Results in a timely manner to understand the business operations and financial performance of the Group.

Resumption Plan

The Company has been working with its professional advisers to address the Resumption Guidance. The Company will seek to resume trading of the Shares on the Stock Exchange as soon as possible. Further announcement(s) will be made by the Company to update the Shareholders and the public on, among others, the resumption progress of the Company as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange was suspended with effect from 9:00 a.m. on 20 March 2026 and will continue to be suspended, pending the fulfilment of the Resumption Guidance and the grant of approval of the Stock Exchange for the resumption of trading of the Shares. For further details in relation to the Resumption Guidance, please refer to the announcement of the Company dated 18 May 2026.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
Honliv Healthcare Management Group Company Limited
Qin Yan
Chairman

Hong Kong, 18 June 2026

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Qin Yan, Mr. Wang Zhongtao and Ms. Li Yanhong as the executive Directors, Mr. Qin Hongchao as the non-executive Director and Mr. Zhao Chun, Mr. Sun Jigang and Mr. Jiang Tianfan as the independent non-executive Directors.